Comparative Pharmacology
Head-to-head clinical analysis: GYNE LOTRIMIN 3 versus ITRACONAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNE LOTRIMIN 3 versus ITRACONAZOLE.
GYNE-LOTRIMIN 3 vs ITRACONAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing membrane permeability.
Inhibits fungal cytochrome P450-dependent 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, disrupting fungal cell membrane synthesis.
Intravaginal: one applicatorful (5 g of 2% cream) or one suppository (200 mg) once daily at bedtime for 3 days.
200 mg orally once daily; for life-threatening infections, can be increased to 200 mg three times daily for first 3 days then twice daily. IV: 200 mg IV every 12 hours for 2 days, then 200 mg IV once daily.
None Documented
None Documented
Clinical Note
moderateItraconazole + Tranilast
"The risk or severity of adverse effects can be increased when Itraconazole is combined with Tranilast."
Clinical Note
moderateItraconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Itraconazole is combined with Tolfenamic acid."
Clinical Note
moderateItraconazole + Nimesulide
"The risk or severity of adverse effects can be increased when Itraconazole is combined with Nimesulide."
Clinical Note
moderateTerminal elimination half-life is 3.5–5 hours for topical administration; systemic absorption is minimal (<0.5%), so half-life reflects local clearance.
Terminal elimination half-life of itraconazole is approximately 24-36 hours after a single dose, but upon chronic dosing, the half-life increases to 34-42 hours due to saturable metabolism. For the active metabolite hydroxyitraconazole, half-life is similar. This prolonged half-life supports once- or twice-daily dosing.
Clotrimazole is primarily excreted via feces (biliary elimination) as metabolites, with approximately 0.5% excreted renally as unchanged drug.
Itraconazole is extensively metabolized in the liver; the primary route of elimination is fecal (approximately 54% as metabolites, 18% as unchanged drug). Renal excretion accounts for about 35% of the dose, with <1% as unchanged drug. Bilary excretion also contributes.
Category C
Category D/X
Azole Antifungal
Azole Antifungal
Itraconazole + Risedronic acid
"The risk or severity of adverse effects can be increased when Itraconazole is combined with Risedronic acid."